ManageEngine RecoveryManager Plus
RecoveryManager Plus keeps widening its backup coverage across the Microsoft identity estate.
Comparison · Analytics
DoseFinding vs Omni
A side-by-side editorial comparison of DoseFinding and Omni — release velocity, themes, recent moves, and the top alternatives to consider.
DoseFinding vs Omni: at a glance
What is DoseFinding?
New stewardship at openpharma, then two releases adding the methods MCP-Mod was missing
DoseFinding implements MCP-Mod and related dose-response methodology for clinical trial design and analysis. In 2024 it changed hands — Marius Thomas took over as maintainer, Novartis was recorded as copyright holder and funder, and the package moved to the openpharma GitHub organisation with roxygen documentation and a proper NEWS file. The two releases since have added substantive methodology: model averaging for dose-response fitting in 1.3-1, and conditional and predictive power for interim analyses in 1.4-1.
What is Omni?
Omni ships weekly, and almost every week the headline item is an AI feature.
Omni publishes a dated weekly digest whose body is a single line listing that week's items, so each entry compresses several releases into a sentence. Across the window the pattern is unmistakable: AI-powered semantic model generation reaching general availability, AI Routines creatable from chat and deliverable to Slack, AI model suggestion endpoints, AI credit controls scoped to embed entity groups and individual users, AI Evals on Azure, and MCP surfaces appearing both in-app and as a searchDashboards tool. The most recent week breaks that streak — default filters on composite topics, stopping a running dashboard query, full-screen preview editing — the first digest in two months led by conventional BI work.
DoseFinding vs Omni: editorial side-by-side
DoseFinding
0.0ANALYTICS
New stewardship at openpharma, then two releases adding the methods MCP-Mod was missing
◆ Current state
DoseFinding implements MCP-Mod and related dose-response methodology for clinical trial design and analysis. In 2024 it changed hands — Marius Thomas took over as maintainer, Novartis was recorded as copyright holder and funder, and the package moved to the openpharma GitHub organisation with roxygen documentation and a proper NEWS file. The two releases since have added substantive methodology: model averaging for dose-response fitting in 1.3-1, and conditional and predictive power for interim analyses in 1.4-1.
◆ Where it's heading
The pattern before the handover was maintenance — R-devel compliance, a bug fix, a link. After it, each release carries a named methodological addition with an acknowledged contributor, plus documentation to match: a longitudinal analysis vignette shipped alongside the interim power work. Housekeeping continues underneath, mostly clearing deprecated ggplot2 interfaces, aes_string in one release and qplot in the next.
◆ Prediction
Given the last two releases each added one method with a supporting vignette, expect the next to follow the same shape. Both additions so far extend the package beyond fixed dose-response fitting, so adaptive and interim methodology is the more likely direction.
Omni
6.3ANALYTICS
Omni ships weekly, and almost every week the headline item is an AI feature.
◆ Current state
Omni publishes a dated weekly digest whose body is a single line listing that week's items, so each entry compresses several releases into a sentence. Across the window the pattern is unmistakable: AI-powered semantic model generation reaching general availability, AI Routines creatable from chat and deliverable to Slack, AI model suggestion endpoints, AI credit controls scoped to embed entity groups and individual users, AI Evals on Azure, and MCP surfaces appearing both in-app and as a searchDashboards tool. The most recent week breaks that streak — default filters on composite topics, stopping a running dashboard query, full-screen preview editing — the first digest in two months led by conventional BI work.
◆ Where it's heading
Two things have been happening in parallel and they are related. Omni pushed AI into the modelling layer rather than only the query layer, which is what semantic model generation reaching GA signified, then built the commercial and access controls those features require — credit limits per user and per embed entity group arrived within weeks of the capabilities that consume them. The MCP work points at a third direction, exposing Omni's content to external agents rather than only serving its own chat. The latest week's return to filters and query controls suggests the AI surface has reached the point where the surrounding product has to catch up to it.
◆ Prediction
With searchDashboards already shipped as an MCP tool, more of Omni's catalog is the obvious next thing to expose that way, and credit controls should keep extending to cover newer AI surfaces. Whether the non-AI week is a pause or a genuine rebalancing is not something one digest can settle.
Alternatives to DoseFinding and Omni
Other Analytics products tracked by Sparkpulse, ranked by recent ship velocity. Each card links to a full editorial trajectory and lets you pivot into a head-to-head comparison with either DoseFinding or Omni.
silx
silx settles into maintenance a release after its PySide6 migration
Plotly
Plotly is turning its cloud into a metered compute platform with an enterprise on-ramp.
aniread
aniread stops asking you to know which tracker wrote the file
Rho
Rho's release machinery finally produced a stable build — and it shipped no new product.
Usermaven
Usermaven closed the loop: data comes in from anywhere, and now it goes back out.
See all DoseFinding alternatives → · See all Omni alternatives →
Recent activity from DoseFinding and Omni
Latest ship moves from both products, interleaved chronologically. ⚡ = editorial spark.
- 15h agoOmniOmni adds default filters on composite topics and query stopping
- 8d agoOmniOmni adds presentation mode and a searchDashboards MCP tool
- 15d agoOmniOmni adds AI credit controls per user and embed entity group
- 22d agoOmniAI semantic model generation goes generally available in Omni ⚡
- 29d agoOmniOmni adds AI suggestion endpoints and OAuth for database connections
- 1mo agoOmniOmni brings AI routines to Slack and adds in-app MCP settings
- 1y agoDoseFindingConditional and predictive power for interim analyses
- 1y agoDoseFindingModel averaging arrives for dose-response fitting ⚡
- 1y agoDoseFindingPackage moves to openpharma under new maintainership
- 2y agoDoseFindingCompliance update for R-devel
- 3y agoDoseFindingpowMCTBinCount bug fix
Frequently asked questions
What is the difference between DoseFinding and Omni?
They serve adjacent needs but don't currently overlap on shipped themes. Omni is currently shipping more aggressively (velocity 6.3 vs 0.0), with 1 editorial sparks in the last 30 days against 0. See the at-a-glance table above for a side-by-side breakdown of velocity, recent sparks, and editorial themes.
Is DoseFinding better than Omni?
Sparkpulse doesn't pick a winner — we score release velocity, not feature parity. Omni is currently shipping more aggressively (velocity 6.3 vs 0.0), with 1 editorial sparks in the last 30 days against 0. For your specific use case, the alternatives sections above list other Analytics products to evaluate alongside.
What are the best alternatives to DoseFinding?
Top DoseFinding alternatives in Analytics are ranked by recent ship velocity. Browse the "DoseFinding alternatives" section above for the current picks, or visit /alternatives/dosefinding for the full list with editorial commentary on each.
What are the best alternatives to Omni?
Top Omni alternatives in Analytics are ranked by recent ship velocity. Browse the "Omni alternatives" section above for the current picks, or visit /alternatives/omni for the full list with editorial commentary on each.